Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

(2013) Sender Herschorn et al.   UROLOGY

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

(2012) Vik Khullar et al.   EUROPEAN UROLOGY

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Reviewing the ICS 2002 terminology report: The ongoing debate

(2009) Paul Abrams et al.   NEUROUROLOGY AND URODYNAMICS

Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses

(2008) Stephen P McKenna et al.   Health and Quality of Life Outcomes

The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis

(2008) Tracey Young et al.   QUALITY OF LIFE RESEARCH

Estimating a Preference-Based Single Index from the Overactive Bladder Questionnaire

(2008) Yaling Yang et al.   VALUE IN HEALTH